Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020

April 2020 | 503 pages | ID: I9B605CB5E1EN
Global Markets Direct

Abstracts

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 14, 30, 4, 95, 18 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
• The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Idiopathic Pulmonary Fibrosis - Overview
Idiopathic Pulmonary Fibrosis - Therapeutics Development
Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
Idiopathic Pulmonary Fibrosis - Drug Profiles
Idiopathic Pulmonary Fibrosis - Dormant Projects
Idiopathic Pulmonary Fibrosis - Discontinued Products
Idiopathic Pulmonary Fibrosis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Idiopathic Pulmonary Fibrosis - Pipeline by Abeome Corp, H1 2020
Idiopathic Pulmonary Fibrosis - Pipeline by Accendatech Au Pty Ltd, H1 2020
Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Ltd, H1 2020
Idiopathic Pulmonary Fibrosis - Pipeline by Afimmune Biopharma Ltd, H1 2020
Idiopathic Pulmonary Fibrosis - Pipeline by Algernon Pharmaceuticals Inc, H1 2020
Idiopathic Pulmonary Fibrosis - Pipeline by Altavant Sciences Inc, H1 2020
Idiopathic Pulmonary Fibrosis - Pipeline by Altay Therapeutics Inc, H1 2020
Idiopathic Pulmonary Fibrosis - Pipeline by Amgen Inc, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Abeome Corp
Accendatech Au Pty Ltd
AdAlta Ltd
Afimmune Biopharma Ltd
Algernon Pharmaceuticals Inc
Altavant Sciences Inc
Altay Therapeutics Inc
Amgen Inc
Amplia Therapeutics Ltd
AnaMar AB
Angion Biomedica Corp
Apaxen
Aqua Therapeutics Co Ltd
Aqualung Therapeutics Corp
Ark Biosciences Inc
Arroyo BioSciences LLC
Asahi Kasei Pharma Corp
AstraZeneca Plc
Atrapos Therapeutics LLC
AusBio Ltd
Avalyn Pharma Inc
BerGenBio ASA
Blade Therapeutics Inc
Boehringer Ingelheim International GmbH
Bonac Corp
BreStem Therapeutics Inc
Bristol-Myers Squibb Co
Celdara Medical LLC
CellCure
Certa Therapeutics Pty Ltd
Chiesi Farmaceutici SpA
Chrysalis Pharma SAS
Citryll BV
CohBar Inc
Collaborations Pharmaceuticals Inc
Compugen Ltd
CrystalGenomics Inc
Daewoong Pharmaceutical Co Ltd
EmphyCorp Inc
Epitracker Inc
Ergon Pharmaceuticals LLC
ethris GmbH
F. Hoffmann-La Roche Ltd
FibroGen Inc
FibroStatin SL
Galapagos NV
Galecto Biotech AB
GenKyoTex SA
Global Blood Therapeutics Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
HEC Pharm Co Ltd
iBio Inc
Imago Pharmaceuticals Inc
Indalo Therapeutics Inc
Inventiva
iOnctura SA
Ionis Pharmaceuticals Inc
Isarna Therapeutics GmbH
Iterion Therapeutics
Jiangsu Hengrui Medicine Co Ltd
JW Pharmaceutical Corp
Kadmon Corp LLC
KBP BioSciences Co Ltd
Kither Biotech Srl
Kyorin Pharmaceutical Co Ltd
Lamellar Biomedical Ltd
LifeMax Laboratories Inc
Lignamed LLC
Liminal BioSciences Inc
LTT Bio-Pharma Co Ltd
Lung Therapeutics Inc
Max Biopharma Inc
MDI Therapeutics Inc
Medicenna Therapeutics Corp
Metagone Biotech Inc
Metera Pharmaceuticals Inc
Miragen Therapeutics Inc
Mission Therapeutics Ltd
Moerae Matrix Inc
Morphic Holding Inc
National Institutes of Pharmaceutical R&D Co Ltd
NB Health Laboratory Co Ltd
New Amsterdam Sciences Inc
Nogra Pharma Ltd
Novartis AG
Novo Nordisk AS
Nuformix Plc
Oasis Pharmaceuticals LLC
OliX Pharmaceuticals Inc
OncoArendi Therapeutics SA
Opsidio LLC
OptiKira LLC
OROX BioSciences Inc
Osteoneurogen Inc
Palo BioFarma SL
Panorama Research Inc
Pharmaxis Ltd
Pharmicell Co Ltd
Pliant Therapeutics Inc
Prasan Pharmaceutical Consultants LLC
PRISM Pharma Co Ltd
Pulmatrix Inc
RDS2 Solutions Inc
Re-Pharm Ltd
Redx Pharma Plc
Regenasome Pty Ltd
Rejuvenation Technologies Inc
Reviva Pharmaceuticals Inc
Ribomic Inc
Roivant Sciences Ltd
Saje Pharma LLC
Samumed LLC
Segue Therapeutics LLC
Shionogi & Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Silurian Pharmaceuticals Inc
Suzhou Zelgen Biopharmaceutical Co Ltd
SynDevRx Inc
Taiho Pharmaceutical Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
Telocyte LLC
Theravance Biopharma Inc
TiumBio Co Ltd
TRACON Pharmaceuticals Inc
Translate Bio Inc
Unity Biotechnology Inc
Vectus Biosystems Ltd
Vicore Pharma AB
X-Rx Inc
Xfibra Inc
Yungjin Pharm Co Ltd
Zai Lab Ltd